Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance.)

ANNEX
ANNEX
Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1)
in Part 1, the heading of point 1.1.1.4 is replaced by the following:
‘
Chemical name
’;
(2)
in Part 3, Table 3.1 is amended as follows:
(a)
the title of the second column is replaced by the following: ‘Chemical name’;
(b)
the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)
(*)
ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;
(c)
the entry corresponding to index number 607-414-00-6 is deleted;
(d)
the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:
Index No
Chemical name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘006-044-00-7
isoproturon (ISO);
3-(4-isopropylphenyl)-1,1-dimethylurea
251-835-4
34123-59-6
Carc. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H373 (blood)
H400
H410
GHS08
GHS09
Wng
H351
H373 (blood)
H410
M = 10
M = 10’
‘015-101-00-5
phosmet (ISO);
S -[(1,3-dioxo-1,3-dihydro-2 H -isoindol-2-yl)methyl] O , O -dimethyl phosphorodithioate;
O , O -dimethyl- S -phthalimidomethyl phosphorodithioate
211-987-4
732-11-6
Repr. 2
Acute Tox. 4
Acute Tox. 3
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H361f
H332
H301
H370 (nervous system)
H400
H410
GHS08
GHS06
GHS09
Dgr
H361f
H332
H301
H370 (nervous system)
H410
M = 100
M = 100’
‘016-096-00-2
thifensulfuron-methyl (ISO);
methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate
—
79277-27-3
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 100
M = 100’
‘017-011-00-1
sodium hypochlorite, solution … % Cl active
231-668-3
7681-52-9
Skin Corr. 1B
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H314
H318
H400
H410
GHS05
GHS09
Dgr
H314
H410
EUH031
M = 10
M = 1
EUH031:
C ≥ 5 %
B’
‘025-002-00-9
potassium permanganate
231-760-3
7722-64-7
Ox. Sol. 2
Repr. 2
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1
H272
H361d
H302
H400
H410
GHS03
GHS08
GHS07
GHS09
Dgr
H272
H361d
H302
H410’
‘603-180-00-4
colecalciferol;
cholecalciferol;
vitamin D 3
200-673-2
67-97-0
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2
STOT RE 1
H330
H310
H300
H372
GHS06
GHS08
Dgr
H330
H310
H300
H372
inhalation:
ATE = 0,05 mg/L (dusts or mists)
dermal:
ATE = 50 mg/kg bw
oral:
ATE = 35 mg/kg bw
STOT RE 1; H372: C ≥ 3 %
STOT RE 2; H373: 0,3 % ≤ C < 3 %’
‘604-014-00-3
chlorocresol;
4-chloro-m-cresol;
4-chloro-3-methylphenol
200-431-6
59-50-7
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
STOT SE 3
Skin Sens. 1B Aquatic Acute 1
Aquatic Chronic 3
H302
H314
H318
H335
H317
H400
H412
GHS07
GHS05
GHS09
Dgr
H302
H314
H335
H317
H410
M = 1’
‘604-016-00-4
1,2-dihydroxybenzene;
pyrocatechol
204-427-5
120-80-9
Carc. 1Β
Muta. 2
Acute Tox. 3
Acute Tox. 3
Skin Irrit. 2
Eye Irrit. 2
H350
H341
H311
H301
H315
H319
GHS08
GHS06
Dgr
H350
H341
H311
H301
H315
H319
oral:
ATE = 300 mg/kg bw
dermal:
ATE = 600 mg/kg bw’
‘604-090-00-8
4- tert -butylphenol
202-679-0
98-54-4
Repr. 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 1
H361f
H315
H318
H410
GHS08
GHS05
GHS09
Dgr
H361f
H315
H318
H410
M = 1’
‘605-003-00-6
acetaldehyde;
ethanal
200-836-8
75-07-0
Flam. Liq. 1
Carc. 1B
Muta. 2
STOT SE 3
Eye Irrit. 2
H224
H350
H341
H335
H319
GHS02
GHS08
GHS07
Dgr
H224
H350
H341
H335
H319’
‘606-047-00-9
2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone
404-360-3
119313-12-1
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410’
‘607-096-00-9
maleic anhydride
203-571-6
108-31-6
Acute Tox. 4
STOT RE 1
Skin Corr. 1B
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1A
H302
H372 (respiratory system) (inhalation)
H314
H318
H334
H317
GHS07
GHS08
GHS05
Dgr
H302
H372 (respiratory system) (inhalation)
H314
H334
H317
EUH071
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-103-00-5
succinic anhydride
203-570-0
108-30-5
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1
H302
H314
H318
H334
H317
GHS07
GHS05
GHS08
Dgr
H302
H314
H334
H317
EUH071’
‘607-113-00-X
isobutyl methacrylate
202-613-0
97-86-9
Flam. Liq. 3
STOT SE 3
Skin Irrit. 2
Skin Sens. 1B
H226
H335
H315
H317
GHS02
GHS07
Wng
H226
H335
H315
H317
D’
‘607-373-00-4
quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate
414-200-4
200509-41-7
Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361fd
H302
H373
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361fd
H302
H373
H410
M = 1
M = 1’
‘613-167-00-5
reaction mass of 5-chloro-2-methyl-2 H -isothiazol-3-one and 2-methyl-2 H -isothiazol-3-one (3:1)
—
55965-84-9
Acute Tox. 2
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A Aquatic Acute 1
Aquatic Chronic 1
H330
H310
H301
H314
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H310
H301
H314
H317
H410
EUH071
Skin Corr. 1C; H314: C ≥ 0,6 %
Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %
Eye Dam. 1; H318: C ≥ 0,6 %
Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100
B’
‘613-205-00-0
propiconazole (ISO); (2 RS ,4 RS ;2 RS ,4 SR )-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1 H -1,2,4-triazole
262-104-4
60207-90-1
Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H302
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H360D
H302
H317
H410
M = 1
M = 1’
‘614-001-00-4
nicotine (ISO);
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
200-193-3
54-11-5
Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
Aquatic Chronic 2
H330
H310
H300
H411
GHS06
GHS09
Dgr
H330
H310
H300
H411
inhalation:
ATE = 0,19 mg/L (dusts or mists)
dermal:
ATE = 70 mg/kg bw
oral:
ATE = 5 mg/kg bw’
(e)
the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:
Index No
Chemical name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘604-094-00-X
isoeugenol; [1]
( E )-2-methoxy-4-(prop-1-enyl)phenol; [2]
( Z )-2-methoxy-4-(prop-1-enyl)phenol [3]
202-590-7 [1]
227-678-2 [2]
227-633-7 [3]
97-54-1 [1]
5932-68-3 [2]
5912-86-7 [3]
Skin Sens. 1A
H317
GHS07
Wng
H317
Skin Sens. 1A; H317: C ≥ 0,01 %’
‘607-724-00-1
2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1 R ,3 R )-2,2-dimethyl-3-[(1 Z )-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin
—
240494-71-7
Acute Tox. 4
Acute Tox. 3
STOT SE 1
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H370 (nervous system)
H373
H400
H410
GHS06
GHS08
GHS09
Dgr
H332
H301
H370 (nervous system)
H373
H410
M = 100
M = 100’
‘607-725-00-7
isopropyl (2 E ,4 E ,7 S )-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S -methoprene
—
65733-16-6
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 1’
‘607-726-00-2
pinoxaden (ISO);
8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7 H -pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate
—
243973-20-8
Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
STOT SE 3
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 3
H361d
H332
H302
H319
H335
H317
H400
H412
GHS08
GHS07
GHS09
Wng
H361d
H332
H302
H319
H335
H317
H410
inhalation:
ATE = 4,63 mg/L (dusts or mists)
oral:
ATE = 500 mg/kg bw
M = 1’
‘607-727-00-8
tetramethrin (ISO);
(1,3-dioxo-1,3,4,5,6,7-hexahydro-2 H -isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate
231-711-6
7696-12-0
Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H371 (nervous system) (inhalation)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H371 (nervous system) (inhalation)
H410
M = 100
M = 100’
‘607-728-00-3
(1,3,4,5,6,7-hexahydro-1,3-dioxo- 2H -isoindol-2-yl)methyl (1 R - trans )-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate
214-619-0
1166-46-7
Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H371 (nervous system) (inhalation)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H371 (nervous system) (inhalation)
H410
M = 100
M = 100’
‘607-729-00-9
mesosulfuron-methyl (ISO);
methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)- p -toluate;
—
208465-21-8
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 100
M = 100’
‘607-730-00-4
spirodiclofen (ISO);
3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate
—
148477-71-8
Carc. 1B
Repr. 2
STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1
H350
H361f
H373
H317
H410
GHS08
GHS07
GHS09
Dgr
H350
H361f
H373
H317
H410
M = 10’
‘607-731-00-X
sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl ( EZ )-sulfanilylcarbonimidate; asulam-sodium
218-953-8
2302-17-2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1
M = 1’
‘607-732-00-5
salicylic acid
200-712-3
69-72-7
Repr. 2
Acute Tox. 4
Eye Dam. 1
H361d
H302
H318
GHS08
GHS07
GHS05
Dgr
H361d
H302
H318’
‘608-068-00-9
flutianil (ISO);
(2 Z )-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile
—
958647-10-4
Aquatic Chronic 1
H410
GHS09
Wng
H410
M = 100’
‘612-293-00-8
reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine
447-920-2
-
Repr. 2
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
H361f
H302
H314
H318
GHS08
GHS07
GHS05
Dgr
H361f
H302
H314
EUH071’
‘613-326-00-9
2-methylisothiazol-3(2 H )-one
220-239-6
2682-20-4
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H330
H311
H301
H314
H318
H317
H400
H410
GHS05
GHS06
GHS09
Dgr
H330
H311
H301
H314
H317
H410
EUH071
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 10
M = 1’
‘613-327-00-4
pyroxsulam (ISO);
N -(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide
—
422556-08-9
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 100
M = 100’
‘613-328-00-X
1-vinylimidazole
214-012-0
1072-63-5
Repr. 1B
H360D
GHS08
Dgr
H360D
Repr. 1B; H360D: C ≥ 0,03 %’
‘616-224-00-2
amisulbrom (ISO);
3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)- N,N -dimethyl-1 H -1,2,4-triazole-1-sulfonamide
—
348635-87-0
Carc. 2
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H319
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H319
H410
M = 10
M = 10’
Schedules & Appendices

Cite this act
